Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 9/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3923882 | 1.00 | CTSL (0.51) | CTSLTACR1GAARAB9ACYP26A1 | |
| SCHEMBL3927855 | 0.84 | TACR1 (0.56) | CTSLTACR1GAARAB9AACE | |
| SCHEMBL7604376 | 0.84 | TACR1 (0.56) | CTSLTACR1GAARAB9AACE | |
| SCHEMBL3927028 | 0.83 | CTSL (0.71) | CTSLGAARAB9AACE | |
| SCHEMBL28790851 | 0.83 | CTSL (0.71) | CTSLGAARAB9AACE | |
| SCHEMBL29188972 | 0.82 | CYP26A1 (0.54) | CTSLGAARAB9ACYP26A1SMN1; SMN2 | |
| SCHEMBL1784498 | 0.82 | CTSL (0.62) | CTSLGAARAB9AACE | |
| SCHEMBL30064651 | 0.82 | CTSL (0.62) | CTSLGAARAB9AACE | |
| SCHEMBL1796825 | 0.82 | CTSL (0.62) | CTSLGAARAB9AACE | |
| SCHEMBL3935180 | 0.82 | CTSL (0.62) | CTSLGAARAB9AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420424-B1 | ADMINISTERING PHENYLALANINE AMIDE DERIVATIVES (SUCH AS S-ETHYL-2-AMINO-3-(4-CHLOROPHENYL)PROPIONATE HYDROCHLORIDE) TO TREAT ALLERGIC DISORDERS, INCLUDING ASTHMA, RHINITIS, DERMATITUS, AND PRURITIS | SMITHKLINE BEECHAM CORPORATION | 2002-07-16 | — | — | US | claimed |
| JP-2002512960-A | — | — | 2002-05-08 | — | — | JP | claimed |
| EP-1073434-A1 | CCR-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-02-07 | — | — | EP | claimed |
| WO-1999055330-A1 | CCR-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-04 | — | — | WO | claimed |
| EP-1691199-B1 | METHOD OF PREDICTING SPOT FORMATION ON THE SKIN WITH THE USE OF SPOT SITE-ACCELERATING GENES AS INDICATION AND METHOD OF SCREENING INHIBITOR FOR SPOT FORMATION ON THE SKIN | SHISEIDO CO LTD (JP) | 2009-04-01 | — | — | EP | disclosed |
| US-20070249915-A1 | Inhibitors | SHISEIDO COMPANY, LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1691199-A1 | METHOD OF PREDICTING SPOT FORMATION ON THE SKIN WITH THE USE OF SPOT SITE-ACCELERATING GENES AS INDICATION AND METHOD OF SCREENING INHIBITOR FOR SPOT FORMATION ON THE SKIN | SHISEIDO COMPANY LIMITED (JP) | 2006-08-16 | — | — | EP | disclosed |
| US-6420424-B1 | ADMINISTERING PHENYLALANINE AMIDE DERIVATIVES (SUCH AS S-ETHYL-2-AMINO-3-(4-CHLOROPHENYL)PROPIONATE HYDROCHLORIDE) TO TREAT ALLERGIC DISORDERS, INCLUDING ASTHMA, RHINITIS, DERMATITUS, AND PRURITIS | SMITHKLINE BEECHAM CORPORATION | 2002-07-16 | — | — | US | disclosed |
| EP-1073434-A1 | CCR-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055330-A1 | CCR-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-04 | — | — | WO | disclosed |